ATOS Atossa Therapeutics Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

ESG framework	Mentions in filings
Sustainability Accounting Standards Board (SASB)	❌
Global Reporting Initiative (GRI)	❌
Task Force on Climate-related Financial Disclosures (TCFD)	❌
UN Sustainable Development Goals (SDGs)	❌

ESG term mentions

In last year of SEC filings

Agriculture Environment Forest Materials Nature Offset Pandemic Raw Materials Waste Access Affordability Benefits Black California Consumer Privacy Act Charitable Citizenship Community Culture Customer Customer Satisfaction Data Privacy Data Security Death Disability Diversity Employee Engagement Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Minority Pay for Performance Privacy Product Quality Recall Recruitment Reimbursement Retirement Safety Satisfaction Skilled Skills Social Societal Society Supplier Supply Chain Talent Union Volunteer Women Anti-corruption Assessment Assurance Audit Bonus Bribery Classified Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Incentive Independence Independent Innovate Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Procurement Proxy Contest Purpose Quality Standard R&D Reputation Reputational Risk Research and Development Responsibility Responsible Strategy Sustainable Tax Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 15, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). The following items of business were considered and voted upon at the Annual Meeting: (1) the election of two Class II directors named in the proxy statement related to the Annual Meeting; (2) the ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020; (3) the approval of the 2020 Atossa Therapeutics, Inc. 2020 Stock Incentive Plan; (4) to conduct an advisory (non-binding) vote on the compensation of our named executive officers as described in the proxy statement related to the Annual Meeting.

The number of shares of common stock entitled to vote at the Annual Meeting was 9,130,984. The number of shares of common stock present or represented by valid proxy at the annual meeting was 6,206,823. All proposals passed. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:

(i)

Election of two Class II Directors

The stockholders elected two Class II directors as set forth below:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Stephen J. Galli, M.D.	2,215,692	489,918	3,501,213
Richard I. Steinhart	2,201,154	504,456	3,501,213

Nominee

Votes For

Votes
Withheld

Broker

Non-Votes

Stephen J. Galli, M.D.

2,215,692

489,918

3,501,213

Richard I. Steinhart

2,201,154

504,456

3,501,213

(ii)

Ratification of Auditors

The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 as set forth below:

Votes For	Votes Against	Abstain	Broker Non-Votes
5,674,903	404,566	127,354	0

(iii)

Approve the Atossa Therapeutics, Inc. 2020 Stock Option and Incentive Plan and to Increase Authorized Shares under Option Plan

The stockholders approved the 2020 Stock Incentive Plan as follows:

Votes For	Votes Against	Abstain	Broker Non-Votes
1,515,688	1,109,012	80,910	3,501,213

(iv)

Non-binding Vote on Executive Compensation

The stockholders approved an advisory non-binding vote on executive compensation as follows:

Votes For	Votes Against	Abstain	Broker Non-Votes
1,475,800	1,136,798	93,012	3,501,213

* * *